Search | IOVS | ARVO Journals

Showing 1 – 20 of 45

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Primary open angle glaucoma polygenic risk score can identify individuals at low risk of disease onset in the Ocular Hypertension Treatment Study

Nazlee Zebardast; Sayuri Sekimitsu; Kanza Aziz; Yan Zhao; Rishabh Singh; John H Fingert; Mae O Gordon; Michael A Kass; Todd E Scheetz; Ayellet Segre; James D Brandt; Janey L Wiggs

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):996.

ARVO Annual Meeting Abstract June 2024

Ocular Hypertension Treatment Study: 20 yr quality of life (QoL) outcomes

Mae O Gordon; Feng Gao; Michael A Kass; Julia Huecker; Pradeep Y Ramulu; Stuart Keith Gardiner; Linda M Zangwill

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4622.

ARVO Annual Meeting Abstract June 2023

Baseline visual field patterns identified by archetypal analysis are associated with glaucoma onset and progression in the Ocular Hypertension Treatment Study

Rishabh Singh; Yan Zhao; John H Fingert; Mae O Gordon; Michael A Kass; Yuyang Luo; Ayellet V. Segre; Janey L Wiggs; Tobias Elze; Nazlee Zebardast

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):349.

ARVO Annual Meeting Abstract June 2023

Prediction model of visual field progression in the Ocular Hypertension Treatment Study

Mae O Gordon; Dale K Heuer; Eve J Higginbotham; Richard K Parrish; Chris A Johnson; Lei Liu; Michael A Kass

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):104.

ARVO Annual Meeting Abstract June 2022

Pre- and Post-POAG Rate of Visual Field Progression in the Ocular Hypertension Treatment (OHTS) Study

Mae e Gordon; James David Brandt; Dale K Heuer; Eve J higginbotham; Richard K Parrish II; Chris A Johnson; John L Keltner; Julia Huecker; Michael A Kass

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3495.

ARVO Annual Meeting Abstract June 2022

Novel risk factor gene for POAG identified with GWAS of Ocular Hypertension Treatment Study

John H Fingert; Adam Hedberg-Buenz; Benjamin Roos; Erin Boese; Nathan Sears; Andrew Pouw; Young H Kwon; Wallace Alward; Robert F Mullins; Edwin M Stone; Michael G. Anderson; Mae Gordon; Michael A Kass; Kai Wang; Todd E Scheetz

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4017 – A0359.

ARVO Annual Meeting Abstract July 2018

The Ocular Hypertension Treatment Study: Aging and Reliability of Visual Fields

Mae O. Gordon; Julia Huecker; Kimberly Plumb; Laura Lemming; Michael A Kass; John L Keltner; Michael Wall; Chris A Johnson

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3025.

ARVO Annual Meeting Abstract June 2017

A Novel Quantitative Approach for Analyzing Glaucomatous Disc Hemorrhages: Identifying the Source of the Blood

Jonathan Chou; Clara C Cousins; John B Miller; Lucy Q Shen; Brian J Song; Mae O Gordon; Michael A Kass; Louis R Pasquale

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3982.

Genetics August 2016

A Common Variant in MIR182 Is Associated With Primary Open-Angle Glaucoma in the NEIGHBORHOOD Consortium

PDF

Yutao Liu; Jessica Cooke Bailey; Inas Helwa; W. Michael Dismuke; Jingwen Cai; Michelle Drewry; Murray H. Brilliant; Donald L. Budenz; William G. Christen; Daniel I. Chasman; John H. Fingert; Douglas Gaasterland; Terry Gaasterland; Mae O. Gordon; Robert P. Igo, Jr; Jae H. Kang; Michael A. Kass; Peter Kraft; Richard K. Lee; Paul Lichter; Sayoko E. Moroi; Anthony Realini; Julia E. Richards; Robert Ritch; Joel S. Schuman; William K. Scott; Kuldev Singh; Arthur J. Sit; Yeunjoo E. Song; Douglas Vollrath; Robert Weinreb; Felipe Medeiros; Gadi Wollstein; Donald J. Zack; Kang Zhang; Margaret A. Pericak-Vance; Pedro Gonzalez; W. Daniel Stamer; John Kuchtey; Rachel W. Kuchtey; R. Rand Allingham; Michael A. Hauser; Louis R. Pasquale; Jonathan L. Haines; Janey L. Wiggs
TAGS: micrornas, neighborhood, open-angle glaucoma, glaucoma, body tissue, hypertension, exosomes
Invest. Ophthalmol. Vis. Sci.. 2016; 57(10):4528-4535. https://doi.org/10.1167/iovs.16-19688

Includes: Supplemental Content

Glaucoma July 2015

Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension

PDF

Mark Christopher; Michael D. Abràmoff; Li Tang; Mae O. Gordon; Michael A. Kass; Donald L. Budenz; John H. Fingert; Todd E. Scheetz
TAGS: ocular hypertension, open-angle glaucoma, optic disk
Invest. Ophthalmol. Vis. Sci.. 2015; 56(8):4470-4479. https://doi.org/10.1167/iovs.14-16142

ARVO Annual Meeting Abstract June 2015

Proportion of Non-Responders to Beta-blockers and Prostaglandin Analogs in OHTS, CIGTS, and Enrollees in a United States Managed Care Plan.

Matthew G J Trese; Andrew Lewis; David M Reed; Taylor Blachley; Michael A Kass; David C Musch; Mae O Gordon; Joshua D Stein; Sayoko Eileen Moroi

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5694.

ARVO Annual Meeting Abstract June 2015

The Ocular Hypertension Treatment Study (OHTS): Improving prediction of which participants who developed glaucoma will/will not have visual field (VF) progression in 5 years

Feng Gao; Philip Miller; Julia Beiser Huecker; Michael A Kass; Mae O Gordon

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3694.

ARVO Annual Meeting Abstract April 2014

TMCO1 is associated with POAG in the Ocular Hypertension Treatment Study (OHTS)

John H Fingert; Kai Wang; Ben Faga; Lizette Ortega; Mae O Gordon; Michael A Kass; Todd Scheetz

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2145.

ARVO Annual Meeting Abstract April 2014

The Ocular Hypertension Treatment Study (OHTS): Longitudinal analyses of mean deviation (MD) loss and its association with visual acuity (VA) and contrast sensitivity (CS) in eyes newly diagnosed with primary-open angle glaucoma (POAG)

Mae O Gordon; J Phiilip Miller; Julia Beiser; Michael A Kass; Feng Gao; Ocular Hypertension Treatment Study

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5647.

Glaucoma February 2013

Series Length Used during Trend Analysis Affects Sensitivity to Changes in Progression Rate in the Ocular Hypertension Treatment Study

PDF

Stuart K. Gardiner; Shaban Demirel; Carlos Gustavo De Moraes; Jeffrey M. Liebmann; George A. Cioffi; Robert Ritch; Mae O. Gordon; Michael A. Kass; for the Ocular Hypertension Treatment Study Group
TAGS: eye, ocular hypertension, trend, universities, ophthalmology
Invest. Ophthalmol. Vis. Sci.. 2013; 54(2):1252-1259. https://doi.org/10.1167/iovs.12-10218

Clinical Trials April 2012

Effect of Treatment on the Rate of Visual Field Change in the Ocular Hypertension Treatment Study Observation Group

PDF

Carlos Gustavo De Moraes; Shaban Demirel; Stuart K. Gardiner; Jeffrey M. Liebmann; George A. Cioffi; Robert Ritch; Mae O. Gordon; Michael A. Kass; For the Ocular Hypertension Treatment Study Group
TAGS: eye, ocular hypertension, open-angle glaucoma, velocity, visual fields
Invest. Ophthalmol. Vis. Sci.. 2012; 53(4):1704-1709. https://doi.org/10.1167/iovs.11-8186

ARVO Annual Meeting Abstract March 2012

Improving the Ocular Hypertension Treatment Study (OHTS) predictive model for the development of Primary Open Angle Glaucoma (POAG)

Mae O. Gordon; Feng Gao; J. Philip Miller; Julia A. Beiser; Michael A. Kass

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4624.

ARVO Annual Meeting Abstract March 2012

Seasonal Variations in Sensitivity and Intraocular Pressure (IOP) in the Ocular Hypertension Treatment Study (OHTS)

Stuart K. Gardiner; Shaban Demirel; Mae O. Gordon; Michael A. Kass; Ocular Hypertension Treatment Study

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1751.

Clinical Trials January 2012

The Rate of Visual Field Change in the Ocular Hypertension Treatment Study

PDF

Shaban Demirel; Carlos Gustavo V. De Moraes; Stuart K. Gardiner; Jeffrey M. Liebmann; George A. Cioffi; Robert Ritch; Mae O. Gordon; Michael A. Kass; for the Ocular Hypertension Treatment Study
TAGS: eye, ocular hypertension, open-angle glaucoma, visual fields, optic disk
Invest. Ophthalmol. Vis. Sci.. 2012; 53(1):224-227. https://doi.org/10.1167/iovs.10-7117

ARVO Annual Meeting Abstract April 2011

Rates of Visual Field Change in Eyes with Optic Disc Hemorrhage in the Ocular Hypertension Treatment Study

Shaban Demirel; Gustavo V. De Moraes; Stuart K. Gardiner; Jeffrey M. Liebmann; George A. Cioffi; Robert Ritch; Mae O. Gordon; Michael A. Kass; Ocular Hypertension Treatment Study

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):2119.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Primary open angle glaucoma polygenic risk score can identify individuals at low risk of disease onset in the Ocular Hypertension Treatment Study

Ocular Hypertension Treatment Study: 20 yr quality of life (QoL) outcomes

Baseline visual field patterns identified by archetypal analysis are associated with glaucoma onset and progression in the Ocular Hypertension Treatment Study

Prediction model of visual field progression in the Ocular Hypertension Treatment Study

Pre- and Post-POAG Rate of Visual Field Progression in the Ocular Hypertension Treatment (OHTS) Study

Novel risk factor gene for POAG identified with GWAS of Ocular Hypertension Treatment Study

The Ocular Hypertension Treatment Study: Aging and Reliability of Visual Fields

A Novel Quantitative Approach for Analyzing Glaucomatous Disc Hemorrhages: Identifying the Source of the Blood

A Common Variant in MIR182 Is Associated With Primary Open-Angle Glaucoma in the NEIGHBORHOOD Consortium

Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension

Proportion of Non-Responders to Beta-blockers and Prostaglandin Analogs in OHTS, CIGTS, and Enrollees in a United States Managed Care Plan.

The Ocular Hypertension Treatment Study (OHTS): Improving prediction of which participants who developed glaucoma will/will not have visual field (VF) progression in 5 years

TMCO1 is associated with POAG in the Ocular Hypertension Treatment Study (OHTS)

The Ocular Hypertension Treatment Study (OHTS): Longitudinal analyses of mean deviation (MD) loss and its association with visual acuity (VA) and contrast sensitivity (CS) in eyes newly diagnosed with primary-open angle glaucoma (POAG)

Series Length Used during Trend Analysis Affects Sensitivity to Changes in Progression Rate in the Ocular Hypertension Treatment Study

Effect of Treatment on the Rate of Visual Field Change in the Ocular Hypertension Treatment Study Observation Group

Improving the Ocular Hypertension Treatment Study (OHTS) predictive model for the development of Primary Open Angle Glaucoma (POAG)

Seasonal Variations in Sensitivity and Intraocular Pressure (IOP) in the Ocular Hypertension Treatment Study (OHTS)

The Rate of Visual Field Change in the Ocular Hypertension Treatment Study

Rates of Visual Field Change in Eyes with Optic Disc Hemorrhage in the Ocular Hypertension Treatment Study

To View More...

You must be signed into an individual account to use this feature.